No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: A case series

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 2, 2004, Pages 295-310

  Gonzalez Heydrich, Joseph ^a   Pandina, Gahan J ^b   Fleisher, Carl A ^a   Hsin, Olivia ^a   Raches, Darcy ^a   Bourgeois, Blaise F ^a   Biederman, Joseph ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADOLESCENT; AGGRESSION; AGITATION; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; COMPLEX PARTIAL SEIZURE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GRAND MAL SEIZURE; HUMAN; HYPOMANIA; IMPULSE CONTROL DISORDER; LEARNING DISORDER; MALE; MENTAL DISEASE; MYOCLONUS SEIZURE; OUTPATIENT; PANCREATITIS; PSYCHOSIS; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SEIZURES;

EID: 3342913653     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/1044546041649075     Document Type: Review

References (40)

1. Alldredge BK: Seizure risk associated with psychotropic drugs: Clinical and pharmacokinetic considerations. Neurology 53(Suppl 2):S68-S75, 1999.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, and the Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behavior in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
3. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR®). Washington, DC, American Psychiatric Association, 2000.
4. Amery A, Vandenbroucke J, Desbuquoit JL, De Groote J: Pancreatitis during clonidine treatment. Tijdschr Gastroenterol 16:179-185, 1973.
5. Anonymous: Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30: 389-399, 1989.
6. Baker GA, Camfield C, Camfield P, Cramer JA, Elger CE, Johnson AL, Martins da Silva A, Meinardi H, Munari C, Perucca E, Thorbecke R: Commission on Outcome Measurement in Epilepsy, 1994-1997: Final Report. Epilepsia 39: 213-231, 1998.
7. Berent I, Carabeth J, Cordero MM, Cordero R, Sugerman B, Robinson D: Pancreatitis associated with risperidone treatment? (Letter) Am J Psychiatry 154:130-131, 1997.
8. Buitelaar JK: Open-label treatment with risperidone of 26 psychiatrically hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10:19-26, 2000.
9. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CTM: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001.
10. Carpay JA, Vermuelen J, Stroink H, Brouwer OF, Peters AC, Aldenkamp AP, van Donselaar CA, Arts WFM: Seizure severity in children with epilepsy: A parent-completed scale compared with clinical data. Epilepsia 38:346-352, 1997.
11. Centers for Disease Control: 2000 CDC Growth Charts: United States. Revised version, 2001. http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/ datafiles.htm.
12. Cordeiro Q Jr, Elkis H: Pancreatitis and cholestatic hepatitis induced by risperidone. (Letter) J Clin Psychopharmacol 21:529-530, 2001.
13. Drake ME, Hietter SA, Pakalnis A: EEG and evoked potentials in episodic-dyscontrol syndrome. Neuropsychobiology 26:125-128, 1992.
14. Dunn DW, Austin JK: Behavioral issues in pediatric epilepsy. Neurology 53(5 Suppl 2):S96-S100, 1999.
15. Dunn DW, Austin JK, Huster GA: Symptoms of depression in adolescents with epilepsy. J Am Acad Child Adolesc Psychiatry 38:1132-1138, 1999.
16. Eriksson KJ, Koivikko MJ: Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. Epilepsia 38:1275-1282, 1997.
17. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000.
18. Findling RL, Kusumakar V, Daneman D, Moshang T, Binder C, De Smedt G: Normalization of prolactin levels in children after long-term treatment with risperidone. San Francisco (CA), American Academy of Child and Adolescent Psychiatry (AACAP) 49th Annual Meeting, October 22-27, 2002 (poster).
19. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
20. French JA: Proof of efficacy trials: Endpoints. Epilepsy Res 45:53-56, 2001.
21. Gonzalez-Heydrich J, DeMaso DR, Irwin C, Steingard RJ, Kohane IS, Beardslee WR: Implementation of an electronic medical record system in a pediatric psychopharmacology program. Int J Med Inf 57:109-116, 2000.
22. Gordon N: Episodic dyscontrol syndrome. Dev Med Child Neurol 41:786-788, 1999.
23. Hardan A, Johnson K, Johnson C, Hrecznyj B: Case study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 35:1551-1556, 1996.
24. Kim E: Management of psychiatric disorders in epileptic patients. New Direct Ment Health Serv 57:99-108, 1993.
25. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57-61, 1999.
26. Nakashima Y, Howard JM: Drug-induced acute pancreatitis. Surg Gynecol Obstet 145:105-109, 1977.
27. National Institute of Mental Health: CGI (Clinical Global Impression) Scale - NIMH. Psychopharmacol Bull 21:839-843, 1985.
28. Popper CW, Gammon GD, West SA, Bailey CE: Disorders usually first diagnosed in infancy, childhood, or adolescence. In: The American Psychiatric Publishing Textbook of Clinical Psychiatry, 4th ed. Edited by Hales RE, Yudofsky SC. Washington, DC, American Psychiatric Association, 2003, pp. 833-974.
29. Research Units in Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. New Eng J Med 347:314-321, 2002.
30. Schreier HA: Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol 8:49-59, 1998.
31. Shinnar S, Pellock JM: Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol 17(Suppl 1):S4-S17, 2002.
32. Simeon J, Milin R, Walker S: A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 26:267-275, 2002.
33. Spina E, Perucca E: Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43(Suppl 2):37-44, 2002.
34. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, and the Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
35. Stevens JR: Psychiatric aspects of epilepsy. J Clin Psychiatry 49(Suppl 4):49-57, 1988.
36. Thiele EA, Gonzalez-Heydrich J, Riviello JJ Jr: Epilepsy in children and adolescents. Child Adolesc Psychiatr Clin N Am 8:671-694, 1999.
37. Torta R, Keller R: Behavioral, psychotic, and anxiety disorders in epilepsy: Etiology, clinical features, and therapeutic implications. Epilepsia 40(Suppl 10):S2-S20, 1999.
38. Tsopelas ND, Saintfort R, Fricchione GL: The relationship of psychiatric illnesses and seizures. Curr Psychiatry Rep 3:235-242, 2001.
39. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34, 2002.
40. Volkmar FR, Nelson DS: Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 29:127-129, 1990.